Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05936580 · ClinicalTrials.gov registry record · Phase 4
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
A Phase 4 study of Hemophilia A, sponsored by Octapharma.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 15
- Study locations
NCT05936580: Recruiting Phase 4 study of Hemophilia A, sponsored by Octapharma.
NCT05936580 is a Phase 4 study of Hemophilia A that is actively recruiting participants, run by Octapharma. The registered enrollment target is 28 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (69% lower). The trial reports 15 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05936580, a Phase 4 study of Hemophilia A, is actively recruiting participants, sponsored by Octapharma.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 15
- Study locations
Study Summary
Recombinant factor VIII for the prevention of bleeding in women/girls with haemophilia A undergoing major surgery
Primary Outcome
Overall haemostatic efficacy of treatment measured as binary "success" or "failure". The overall perioperative haemostatic efficacy of Nuwiq will be adjudicated by an Independent Data Monitoring Committee (IDMC) and determined using a composite assessment algorithm that considers the surgeon's assessment of intraoperative haemostatic efficacy and the investigator's assessment of postoperative haemostatic efficacy to classify the overall haemostatic efficacy as success or failure.
Conditions Studied
Interventions
- DRUG Nuwiq
Study Locations (15)
Other
- Helsinki University Hospital,Coagulation Disorder Unit - Helsinki
- Avenue de la République - Chambray-lès-Tours
- CHU de Nantes Hôtel-Dieu - Nantes
- Universitätsklinikum Bonn,Institut für Experimentelle Haematologie und Transfusionsmedizin - Bonn
- Gerinnungszentrum Rhein-Ruhr - Duisburg
- Universitätsklinikum Hamburg Eppendorf,II. Medizinische Klinik und Poliklinik - Hamburg
- Aziendo Ospedaliera "Puglieze Ciaccio" - Catanzaro
- Policlinico "P. Giaconne" - Palermo
- Clinical Center for Serbia - Belgrade
- Hospital Universitario la Paz - Madrid
- Hospital Universitario Virgen del Rocio - Seville
- Insel Spital Bern - Bern
- St. James's University Hospital - Leeds
- Centro Hospitalario Pereira Rossell - Montevideo
Texas
- UT Health San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-02 |
| Phase | Phase 4 |
What NCT05936580 shows while recruiting
NCT05936580 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Nuwiq is the first listed.
NCT05936580 lists 15 locations in 2 states (Other, Texas).
Frequently Asked Questions
What is clinical trial NCT05936580 about?
NCT05936580 is a clinical study titled "Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery". Recombinant factor VIII for the prevention of bleeding in women/girls with haemophilia A undergoing major surgery
What is the current status of trial NCT05936580?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2026-04. Estimated completion is 2027-02.
What conditions does trial NCT05936580 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT05936580?
The interventions under investigation include: Nuwiq (DRUG).
Who is sponsoring clinical trial NCT05936580?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05936580 being conducted?
This trial has 15 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05936580's enrollment target sits among peer trials
28 27th of 42 higher than 15 of 42 other Hemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
RECRUITING · Phase 4
-
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
RECRUITING · Phase 4
-
Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
COMPLETED · Phase 4
-
Prophylaxis Regimen for Hemophilia A Patients
COMPLETED · Phase 4
-
Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
COMPLETED · Phase 4
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia